^Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB (1993). "Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy". Cancer Chemotherapy and Pharmacology. 31 (6): 442–444. doi:10.1007/bf00685032. PMID8453682. S2CID23122385.
^Alphin RS, Proakis AG, Leonard CA, Smith WL, Dannenburg WN, Kinnier WJ, et al. (May 1986). "Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility". Digestive Diseases and Sciences. 31 (5): 524–529. doi:10.1007/bf01320319. PMID3698769. S2CID6571531.
^ abCostall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, et al. (July 1987). "The action of dazopride to enhance gastric emptying and block emesis". Neuropharmacology. 26 (7A): 669–677. doi:10.1016/0028-3908(87)90227-9. PMID3114664. S2CID25143512.
^ abCostall B, Domeney AM, Naylor RJ, Tattersall FD (September 1987). "Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs". Neuropharmacology. 26 (9): 1321–1326. doi:10.1016/0028-3908(87)90094-3. PMID2890117. S2CID24621209.